Jakarta, Beritasatu.com – Although not as many people as coronary heart disease sufferers, most cases of heart failure are permanent with a lower life expectancy.
Dr. Siti Elkana Nauli SpJP explained that heart failure is a condition in which the heart’s function in pumping blood is not optimal. The blood that is pumped is no longer able to meet the needs of all body tissues.
“As a result, patients experience symptoms such as fatigue and shortness of breath during activity. The severity of symptoms depends on the stage or stage heart failure, “explained Dr. Siti in a press statement received Monday (9/28/2020).
According to Dr. Siti, research that has been carried out by an association of heart and blood vessel specialists in Indonesia through the registration of heart patient data between 2017 and now, shows that of around 2,000 patients with heart failure, the most common causes are hypertension, coronary heart disease and diabetes.
“The morbidity and mortality rate for heart failure patients is very high. The quality of life is much worse than other heart diseases. The life expectancy for 5 years is only about 50 percent. For inpatients, the mortality rate is even higher, namely 17 percent to 17 percent. 20 percent will die within 30 days of being treated, “he explained.
Furthermore, Dr. Siti said, the cost of treatment and care for heart failure patients was very high. One of the triggers is that they have to be hospitalized over and over again, when their symptoms worsen. The more often the patient is hospitalized, the treatment becomes more difficult and complications increase.
In fact, patients can become resistant to treatment and eventually fall into end-stage heart failure. The goals of heart failure therapy are to reduce mortality and improve the quality of life for patients. Standard therapy for heart failure is medication, implantation of the heart, and heart transplant.
“But for the last two therapies, the costs are very high. Installation of a new pacemaker and advance as left ventricular assist device (LVAD) and heart transplant are not even available in Indonesia, ”he explained.
Professor of the Faculty of Medicine of Udayana Bali, Prof. Dr. Ketut Suastika, added that the development of new drugs that are proven to reduce the morbidity and mortality of heart failure patients is certainly a long-awaited news.
According to Prof. Suastika, one of the most recent studies for the treatment of heart failure came from an anti-diabetic drug from the SGLT2 group, namely Empagliflozin. Initially SGLT2 was indeed an antidiabetic drug. But apparently in its development, this drug is not only useful for lowering blood sugar but also has other positive effects.
“This drug can help remove excess salt through the kidneys, improve blood pressure, and reduce obesity, and many other beneficial effects, including suppressing inflammation. All of these contribute to improving symptoms of heart failure, both in diabetic and non-diabetic patients,” he concluded. Prof. Suastika.
Source: BeritaSatu.com
– .
/data/photo/2020/09/28/5f71cec4271ca.jpg "In the aftermath of a Dangdut Concert, the Deputy Chairperson of the Tegal City DPRD named as a suspect. Page all")